📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
520 announcements match the current filters (relevance ≥ 5).
TTK Healthcare Recommends Rs 10 Dividend; FY26 Net Profit Jumps 24% to Rs 81.66 Crore
TTK Healthcare Limited reported a strong financial performance for the fiscal year ended March 31, 2026, with net profit rising 24.3% to Rs 81.66 crore from Rs 65.68 crore in the previous year. Total income grew to Rs 929.64 crore, supported by steady operations despite exceptional charges related to labor code adjustments. The Board has recommended a final dividend of Rs 10 per share (100% of face value), maintaining its payout policy. Additionally, the company has secured leadership continuity by reappointing Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Recommended a final dividend of Rs 10 per equity share (100%) for the financial year 2025-26.
Annual Net Profit (PAT) increased by 24.3% YoY to Rs 8,165.69 lakhs from Rs 6,568.05 lakhs.
Total Income for FY26 rose to Rs 92,964.11 lakhs compared to Rs 85,728.11 lakhs in the previous fiscal.
Earnings Per Share (EPS) saw significant growth, rising to Rs 57.79 from Rs 46.48.
Reappointed Mr. T T Raghunathan as Executive Chairman for a further term of 5 years effective November 2026.
👀 What to Watch
Investors should take note of the robust 24% growth in net profit and the healthy dividend yield. The company's improved EPS and leadership stability make it a positive prospect for long-term portfolios.
TTK Healthcare FY26 Revenue Up 7% to ₹857 Cr; Net Profit at ₹65.68 Cr; ₹10 Dividend Declared
TTK Healthcare reported a steady 7% growth in annual revenue from operations, reaching ₹857.28 crore for the fiscal year ended March 31, 2026. Net profit for the year declined to ₹65.68 crore from ₹81.66 crore in the previous year, primarily due to a high base in FY25 which included significant one-time gains from land sales. The company maintained its dividend payout, recommending ₹10 per share (100% of face value), and confirmed the re-appointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Revenue from operations grew to ₹85,728.11 lakhs in FY26 compared to ₹80,149.34 lakhs in FY25.
Net Profit after tax stood at ₹6,568.05 lakhs, a decrease from ₹8,165.69 lakhs in the previous fiscal year.
Recommended a dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.
FY26 results include a net exceptional charge of ₹757.87 lakhs related to the implementation of new Labour Codes.
Mr. T T Raghunathan re-appointed as Executive Chairman for a 5-year term effective November 1, 2026.
👀 What to Watch
Investors should focus on the consistent top-line growth while accounting for the fact that the previous year's profit was inflated by one-time asset sales. The steady dividend and management continuity are positive signs for long-term stability.
Sai Parenterals FY26 Revenue Jumps 133% to ₹381 Cr; Targets ₹750 Cr Revenue in FY27
Sai Parenterals reported a transformational FY26 with consolidated revenue growing 133% to ₹381 crore, significantly boosted by the acquisition of Australia-based Noumed Pharmaceuticals. The company is currently executing a ₹440 crore growth capex program, including EU-GMP upgrades in India and a new facility in Adelaide, Australia. Management has issued strong guidance for FY27, targeting ₹750 crore in revenue and 17% EBITDA margins, with FY28 expected to show the full impact of current investments. The integration of Noumed provides access to 451 IP dossiers and major Australian pharmacy networks.
Key Highlights
Consolidated FY26 revenue reached ₹381 crore, up 133% YoY, while standalone PAT grew 64% to ₹17 crore.
Management guidance for FY27 targets ₹750 crore revenue and 17% EBITDA margins.
Executing a ₹440 crore capex program, including ₹111 crore for India upgrades and ₹311 crore for the Adelaide facility.
Acquisition of Noumed Pharmaceuticals adds 451 IP dossiers and distribution access to 2,100 pharmacies in Australia.
Vertical integration benefits and internalization of Noumed's manufacturing are expected to drive significant margin expansion in FY28.
👀 What to Watch
Investors should track the timely commissioning of the Adelaide facility and EU-GMP upgrades in India by Q4 FY27, as these are the primary catalysts for the projected doubling of revenue. The successful integration of Noumed's IP portfolio into the Indian manufacturing base remains a key monitorable for margin improvement.
Share India Securities Credit Rating Downgraded by Acuité; Company Cites Agency Transition
Acuité Ratings has downgraded several debt facilities of Share India Securities to 'Issuer not co-operating' status, including over ₹1,200 crore in Bank Guarantees and ₹150 crore in MLDs. The company has clarified that this downgrade is a result of their decision to transition credit rating services to CRISIL and stop cooperating with Acuité. Share India maintains that many of the facilities rated by Acuité are non-operational or surrendered, and their active ratings with CRISIL remain valid and reaffirmed. This appears to be a procedural conflict between the agency and the company rather than a fundamental credit issue.
Key Highlights
Acuité downgraded ₹1,278 crore of Bank Guarantees from ACUITE A1+ to ACUITE A4+ under 'Issuer not co-operating' status.
Proposed Long Term Loans and Secured Overdrafts downgraded to ACUITE BB+ from ACUITE A+.
₹150 crore Proposed Principal Protected Market Linked Debentures (PP-MLD) downgraded to ACUITE BB+.
Company states it transitioned to CRISIL Ratings Limited and informed Acuité of the same in March 2026.
Share India claims the downgraded facilities are largely non-operational or have already been surrendered.
👀 What to Watch
Investors should focus on the active CRISIL ratings rather than the Acuité downgrade, which appears to be a procedural result of non-cooperation during an agency switch. Monitor for any future updates from CRISIL to ensure credit stability remains intact.
MT Educare Reports Default of ₹32.33 Cr in Borrowings Amid Ongoing Insolvency Process
MT Educare Limited has disclosed a default on principal and interest payments totaling ₹32.33 crores to lenders including Prudence ARC and Axis Bank. The company has been under the Corporate Insolvency Resolution Process (CIRP) since December 16, 2022, following an NCLT order. In addition to direct borrowings, corporate guarantees worth approximately ₹23.99 crores have been invoked against the company. A significant claim of ₹49.72 crores from SVC Bank remains under appeal at the NCLAT after being initially rejected by the NCLT.
Key Highlights
Total outstanding borrowings from banks and financial institutions amount to ₹32.33 crores.
Default to Prudence ARC includes ₹16.44 crores in principal and ₹3.75 crores in interest.
Default to Axis Bank includes ₹7.65 crores in principal and ₹4.51 crores in interest.
Invoked corporate guarantees total ₹23.99 crores for Sri Gayatri Education Society and Lakshya Forum.
Company remains under CIRP with a pending NCLAT decision regarding a ₹49.72 crore claim by SVC Bank.
👀 What to Watch
Investors should exercise extreme caution as the company is in the middle of insolvency proceedings, which often leads to substantial equity dilution or total loss for retail shareholders. The ongoing legal disputes and defaults indicate a high risk of capital loss.
Sai Parenterals Bags 10-Year Order Worth Rs 104.50 Cr from PILL CORP, Philippines
Sai Parenterals Limited has secured a significant international contract from PILL CORP, Philippines, for the supply of anti-TB products. The contract is valued at USD 11 million, which translates to approximately Rs. 104.50 Crores at an exchange rate of Rs. 95 per USD. This is a long-term agreement spanning 10 years on an exclusivity basis, starting from June 1, 2026. The deal provides long-term revenue visibility and strengthens the company's footprint in the international pharmaceutical market.
Key Highlights
Total contract value of USD 11 million (approximately Rs. 104.50 Crores).
10-year exclusive supply agreement for anti-TB products in the Philippines market.
Contract execution is set to commence on June 1, 2026.
Valuation calculated at a fixed exchange rate of Rs. 95 per USD.
The order is from an international entity with no promoter group interest or related party involvement.
👀 What to Watch
Investors should view this as a positive development for long-term revenue stability; however, they should monitor the execution of periodic purchase orders and the impact of currency fluctuations on margins.
Rajdarshan Industries Approves FY26 Results; Re-appoints Internal Auditor & Opens New Office
Rajdarshan Industries Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with the statutory auditors issuing an unmodified opinion. The company confirmed the re-appointment of Mr. Anil Jain as the Internal Auditor for the 2026-27 financial year to maintain internal control standards. Additionally, the company is expanding its operational infrastructure by opening a new administrative office in Udaipur effective June 1, 2026. The board meeting concluded on May 26, 2026, after reviewing both standalone and consolidated performance.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors M/s. Ajay Paliwal & Co issued an audit report with an unmodified opinion for FY26.
Re-appointed Mr. Anil Jain (Membership No. 406311) as Internal Auditor for the 2026-27 financial year.
Announced the opening of a new administrative office at Mumal Tower, Udaipur, effective June 1, 2026.
👀 What to Watch
Investors should examine the full FY26 financial statements to assess the company's revenue growth and profitability trends. The unmodified audit opinion and continuity in internal audit indicate stable corporate governance.
Rajdarshan Industries Reports FY26 Net Loss of ₹17.65 Lakhs as Revenue Declines 63%
Rajdarshan Industries Limited reported a weak financial performance for the fiscal year ended March 31, 2026, with consolidated revenue from operations falling significantly to ₹57.38 Lakhs from ₹157.28 Lakhs in the previous year. The company swung from a net profit of ₹23.49 Lakhs in FY25 to a net loss of ₹17.65 Lakhs in FY26. Total comprehensive income was further impacted by other losses, resulting in a total comprehensive loss of ₹147.96 Lakhs. A significant concern remains regarding ₹3.90 Crores in loans and advances outstanding for over three years for which no provision has been made.
Key Highlights
Consolidated revenue from operations decreased by 63.5% YoY to ₹57.38 Lakhs in FY26.
The company reported a consolidated net loss of ₹17.65 Lakhs versus a profit of ₹23.49 Lakhs in FY25.
Total comprehensive loss for the year stood at ₹147.96 Lakhs compared to a profit of ₹47.77 Lakhs in the prior year.
Management disclosed ₹3.90 Crores in loans and advances outstanding for more than 3 years without provisioning.
Announced the opening of a new administrative office in Udaipur effective June 1, 2026.
👀 What to Watch
Investors should exercise caution as the company has moved into a loss-making position with a sharp decline in core revenue. The lack of provisioning for long-outstanding loans of ₹3.90 Crores is a significant risk factor that could lead to future write-offs.
Hindware Home Innovation FY26 EBITDA Rises 27% to ₹233 Cr; Bathware Debt Reduced to ₹234 Cr
Hindware Home Innovation reported consolidated FY26 revenue of ₹2,510 crore, nearly flat YoY, but saw EBITDA grow 27% to ₹233 crore with margins improving to 9%. The company achieved a turnaround with a PBT of ₹45 crore against a loss of ₹28 crore in FY25. Management has strategically exited loss-making categories like fans and air coolers to focus on high-margin kitchen appliances and water heaters. The Bathware segment remains strong, contributing ₹1,520 crore in revenue with a 10.3% EBITDA margin.
Key Highlights
Consolidated EBITDA grew 27% YoY to ₹233 crore with margins expanding by 200 bps to 9% in FY26.
Net bank debt in the Bathware division decreased by ₹74 crore to ₹234 crore during the fiscal year.
Working capital cycle improved to 89 days from 103 days, driven by better inventory and receivables management.
Management guided for 15-20% revenue growth in the Bathware segment for FY27 with further margin improvement.
Discontinued low-margin categories including fans, air purifiers, and furniture fittings to sharpen focus on kitchen appliances.
👀 What to Watch
Investors should note the significant margin expansion and debt reduction as the company exits non-core, loss-making segments. The strong 15-20% growth guidance for the core Bathware business makes it a key stock to watch for recovery and growth.
Sai Parenterals FY26 Consolidated Revenue Hits ₹381 Cr; Standalone PAT Jumps 64% YoY
Sai Parenterals reported a strong performance for FY26, with consolidated revenue reaching ₹381 crore, significantly aided by the acquisition of Australia-based Noumed Pharmaceuticals. On a standalone basis, the company saw a robust 64% YoY growth in PAT to ₹17 crore, driven by a massive 250% surge in CDMO revenue. The company successfully listed in April 2026 after a ₹285 crore IPO, utilizing funds for capacity expansion and R&D. With 67 dossiers currently under development and a new facility in Adelaide on track for Q4FY27, the company is aggressively targeting regulated markets.
Key Highlights
Consolidated FY26 revenue reached ₹381 crore, with Q4FY26 contributing ₹198 crore following the Noumed consolidation.
Standalone PAT grew 64% YoY to ₹17 crore, while standalone EBITDA increased 23% to ₹33 crore.
CDMO revenue surged by over 250% YoY, reflecting deeper engagement with global customers and long-term contracts.
Expanded portfolio by 93 dossiers in FY26, with 67 additional dossiers currently under development for export-led growth.
Investing ₹111 crore in Unit III expansion and AUD 53 million for a new TGA-approved facility in Australia.
👀 What to Watch
Investors should focus on the successful integration of Noumed and the ramp-up of the CDMO business which is driving higher margins. The progress of the Adelaide facility and EU-GMP upgradations of Indian units are key catalysts for future valuation re-rating.
Amara Raja Q4 Revenue Grows 16% to ₹3,460 Cr; Recommends ₹5.2 Final Dividend
Amara Raja Energy & Mobility (ARE&M) reported a 16% YoY revenue growth in Q4 FY26, reaching ₹3,460 Cr, while Q4 PBT nearly doubled to ₹433 Cr. For the full year FY26, revenue stood at ₹13,549 Cr with a profit before tax of ₹1,307 Cr and an EPS of ₹53.02. The company's new energy business is scaling rapidly, posting a 60% revenue increase, and the board has recommended a final dividend of ₹5.2 per share. Strategic projects like the Giga Corridor and BESS plant are on track, with the R&D center becoming operational next month.
Key Highlights
Q4 FY26 revenue rose 16% YoY to ₹3,460 Cr; Q4 PBT jumped to ₹433 Cr from ₹224 Cr.
Full-year FY26 revenue reached ₹13,549 Cr compared to ₹12,405 Cr in FY25.
New energy business revenue surged by 60% YoY, driven by lithium solutions and telecom expansion.
Board recommended a final dividend of ₹5.2 per share for FY26.
2 GWh cell manufacturing capacity remains on track for commissioning by June 2027.
👀 What to Watch
The stock remains a strong play on the energy transition, with the new energy segment showing high growth potential. Investors should monitor the progress of the Giga factory and the impact of lead price volatility on core margins.
Amara Raja Energy & Mobility Announces ₹5.20 Final Dividend; Sets Record Date for July 27, 2026
Amara Raja Energy & Mobility Limited (ARE&M) has announced a final dividend of ₹5.20 per equity share for the financial year 2025-26, representing a 520% payout on the face value of ₹1. The company has fixed July 27, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the 41st Annual General Meeting (AGM) is scheduled to be held on August 10, 2026. This announcement provides clarity on the timing and quantum of the final return to shareholders for the previous fiscal year.
Key Highlights
Final dividend declared at ₹5.20 per equity share of ₹1 face value (520%)
Record date for dividend eligibility fixed as Monday, July 27, 2026
41st Annual General Meeting (AGM) scheduled for Monday, August 10, 2026
The dividend pertains to the financial year ending March 31, 2026
👀 What to Watch
Investors seeking to benefit from the ₹5.20 dividend should ensure they own the stock before the ex-dividend date, which is typically one business day prior to the July 27 record date.
Amara Raja Q4 FY26 Net Profit Surges to ₹322 Cr; Final Dividend of ₹5.20 Declared
Amara Raja Energy & Mobility Limited (ARE&M) reported a robust performance for Q4 FY26, with revenue from operations rising to ₹3,459.92 crore from ₹2,973.85 crore YoY. Net profit for the quarter nearly doubled to ₹322.33 crore, supported by an exceptional gain of ₹181.15 crore. For the full fiscal year 2025-26, the company achieved a total revenue of ₹13,548.86 crore and a net profit of ₹970.43 crore. The board has recommended a final dividend of ₹5.20 per share, bringing the total dividend for the year to ₹10.60.
Key Highlights
Q4 FY26 revenue from operations grew 16.3% YoY to ₹3,459.92 crore.
Net profit for Q4 FY26 stood at ₹322.33 crore compared to ₹166.81 crore in the previous year.
Full-year FY26 revenue reached ₹13,548.86 crore with a consolidated net profit of ₹970.43 crore.
Recommended a final dividend of ₹5.20 per share (520%), totaling ₹10.60 for the full year.
Earnings per share (EPS) for Q4 FY26 increased significantly to ₹17.61 from ₹9.11 YoY.
👀 What to Watch
Investors should view the steady revenue growth and high dividend payout favorably, though the bottom line was boosted by exceptional items. The company's transition towards energy and mobility solutions continues to reflect in its scale.
Sai Parenterals Q4 PAT Surges 736% to ₹13.25 Cr; FY27 Revenue Target Set at ₹750 Cr
Sai Parenterals reported an exceptional Q4 FY26 with PAT surging 736% YoY to ₹13.25 crore, driven by the successful integration of Noumed (Australia) and a 250% jump in CDMO revenues. Full-year FY26 revenue grew 140% to ₹380.99 crore, reflecting the impact of strategic acquisitions and export growth. The company successfully completed its IPO in March 2026, raising ₹285 crore to fund a massive ₹440 crore capex program. Management has issued aggressive guidance for FY27, targeting ₹750 crore in revenue and an improved EBITDA margin of 17%.
Key Highlights
Q4 FY26 revenue grew 166.65% YoY to ₹197.93 Cr, while PAT increased 736.04% to ₹13.25 Cr.
FY26 consolidated revenue reached ₹380.99 Cr (+140.37% YoY) following the acquisition of Noumed Australia.
Management targets FY27 revenue of ₹750 Cr and EBITDA margins of 17%, nearly doubling current revenue levels.
Ongoing capex of ₹440 Cr includes a new R&D center in India and Australia's largest modern pharmaceutical plant.
CDMO revenues surged by over 250% YoY, supported by 88 new product dossiers added in FY26 and 67 more in the pipeline.
👀 What to Watch
Investors should focus on the company's ability to execute its ₹440 crore capex and achieve the ambitious ₹750 crore revenue target for FY27. The stock remains a high-growth play in the CDMO and injectable space following its recent listing and successful Australian integration.
Sai Parenterals Reports Zero Deviation in Utilization of ₹2,850 Million IPO Proceeds
Sai Parenterals Limited has submitted its statement of deviation for the quarter and year ended March 31, 2026, confirming that IPO funds are being handled as per the offer document. The company raised ₹2,850 million through its Initial Public Offer in late March 2026. As of the reporting date, no funds have been diverted from their original objects, which include significant allocations for capacity expansion and debt repayment. The monitoring agency, India Ratings & Research, and the company's Audit Committee have reviewed and confirmed the status.
Key Highlights
Successfully raised ₹2,850 million through an IPO conducted between March 24 and March 27, 2026.
Confirmed zero deviation or variation in the utilization of proceeds for the period ending March 31, 2026.
Major allocations include ₹1,107.95 million for capacity expansion and ₹356.41 million for loan repayments related to the acquisition of Noumed Pharmaceuticals (Australia).
Allocated ₹180.23 million for the establishment of a new R&D Centre and ₹330 million for working capital requirements.
India Ratings & Research Private Limited is acting as the monitoring agency for the fund utilization.
👀 What to Watch
Investors should track subsequent quarterly filings to ensure the ₹2,850 million is deployed timely into the high-growth capacity expansion and R&D projects as promised.
Sai Parenterals Reports Q3 FY26 Consolidated PAT of ₹33.37 Million Post-IPO
Sai Parenterals Limited has released its first set of financial results post-listing for the quarter and nine months ended December 31, 2025. On a consolidated basis, the company reported a revenue of ₹892.11 million for the quarter, though it faced a loss before tax of ₹16.25 million, which turned into a PAT of ₹33.37 million due to deferred tax credits. The standalone performance remained profitable with a nine-month PAT of ₹68.28 million. A significant development is the completed acquisition of a 74.64% stake in UK-based Noumed Life Sciences for AUD 22 million, which is now reflected in the consolidated figures.
Key Highlights
Consolidated Revenue from Operations for Q3 FY26 stood at ₹892.11 million.
Consolidated Profit After Tax (PAT) for the quarter was ₹33.37 million, supported by a ₹55.57 million deferred tax credit.
Standalone Nine-Month revenue reached ₹1,054.59 million with a PAT of ₹68.28 million.
Completed acquisition of 74.64% stake in Noumed Life Sciences Limited (UK) for an aggregate consideration of AUD 22 million.
The company reported an unmodified audit opinion for the financial year ended March 31, 2026.
👀 What to Watch
Investors should closely monitor the operational integration of the UK-based Noumed Life Sciences, as the consolidated entity is currently reporting losses at the pre-tax level despite high revenue scaling. The stock's performance will likely depend on the company's ability to turn the consolidated operations profitable without relying on tax adjustments.
Sai Parenterals Q3 FY26 Consolidated Revenue at ₹892.1M; Completes Noumed UK Acquisition
Sai Parenterals reported a consolidated revenue of ₹892.11 million for the quarter ended December 31, 2025, with a net profit of ₹33.37 million. The standalone performance for the same quarter showed a revenue of ₹384.79 million and a profit of ₹3.63 million. A major strategic milestone was the completion of a 74.64% stake acquisition in UK-based Noumed Life Sciences Limited for AUD 22 million. As the company was recently listed, year-on-year comparative figures for the previous financial year are not available.
Key Highlights
Consolidated revenue for Q3 FY26 reached ₹892.11 million with a PAT of ₹33.37 million.
Standalone 9-month revenue stood at ₹1,054.59 million with a PAT of ₹68.28 million.
Completed acquisition of 74.64% stake in Noumed Life Sciences (UK) for a total consideration of AUD 22 million.
Consolidated 9-month revenue reported at ₹1,530.71 million, indicating strong contribution from international subsidiaries.
Statutory auditors issued an unmodified opinion on the audited financial results for the year ended March 31, 2026.
👀 What to Watch
Investors should monitor the integration of the Noumed UK acquisition and its impact on consolidated margins in future quarters. As a newly listed entity, focus on the company's ability to maintain revenue growth in the branded generic and CDMO segments.
Share India Appoints Former CBDT Chairman Arun Kumar Jain as Independent Director for 5 Years
Share India Securities has received shareholder approval via postal ballot for key board appointments. Mr. Arun Kumar Jain, a former Chairman of the Central Board of Direct Taxes (CBDT), has been appointed as a Non-Executive Independent Director for a five-year term starting March 05, 2026. Additionally, Mr. Piyush Mahesh Khandelwal has been re-appointed as an Independent Director for another five-year term effective March 03, 2026. These appointments are aimed at strengthening the company's governance framework and regulatory oversight.
Key Highlights
Appointment of Mr. Arun Kumar Jain as Independent Director for a 5-year term starting March 05, 2026
Mr. Jain is a former Chairman of the CBDT with extensive experience in taxation and finance
Re-appointment of Mr. Piyush Mahesh Khandelwal as Independent Director for a second 5-year term
Approval obtained via Postal Ballot with voting concluding on May 21, 2026
👀 What to Watch
The inclusion of a high-profile former tax official on the board enhances the company's corporate governance profile. Investors should view this as a positive step for long-term institutional stability.
Share India Q4 FY26 Consolidated PAT Surges 220% to ₹58 Cr; PMS AUM Crosses ₹100 Cr
Share India Securities reported a robust Q4 FY26 with consolidated revenue rising 74% YoY to ₹416 crore and PAT jumping 220% to ₹58 crore. While full-year consolidated PAT remained flat at ₹324 crore due to fair value adjustments, standalone performance was exceptionally strong with FY26 PAT growing 20% to ₹298 crore. The company is successfully diversifying into Wealth Management, with its PMS already reaching ₹100 crore AUM and a target of ₹200 crore for FY27. Additionally, the new debt market vertical, Share India Cred, has already closed six issues and targets ₹500 crore in volume for the coming year.
Key Highlights
Standalone Q4 revenue grew 103% YoY to ₹383 crore, with standalone PAT up 368% to ₹75 crore.
Consolidated net worth stands strong at ₹2,655 crore as of March 31, 2026.
The uTrade algo-trading platform reached a significant milestone of 5,231 retail clients.
New debt market vertical 'Share India Cred' launched in Q1 FY27 with a target of ₹500 crore in issues.
Applied for AIF CAT-3 license with SEBI, expecting approval and operations to commence by Q2/Q3 FY27.
👀 What to Watch
Investors should focus on the company's successful transition from a pure brokerage to a diversified financial services firm with high-growth verticals like Wealth Management and Debt Markets. The strong Q4 recovery and scaling of the uTrade platform provide a positive outlook for FY27.
Saregama Q4FY26: Revenue up 19% to ₹287 Cr; Adjusted EBITDA grows 31% YoY
Saregama reported a strong Q4FY26 with revenue growing 19% YoY to INR 287 crores and adjusted EBITDA rising 31% to INR 133 crores. The music vertical, which includes licensing and artist management, saw 17% annual revenue growth, supported by the success of the 'Dhurandhar 1' album and the stabilization of streaming revenues. The company completed a strategic investment in Bhansali Productions to secure high-quality Hindi film music for the next 2-3 years. Additionally, Pocket Aces achieved breakeven, and the company is expanding its artist management portfolio to over 300 artists.
Key Highlights
Q4 Revenue grew 19% YoY to INR 287 crores; Adjusted EBITDA rose 31% to INR 133 crores.
Music vertical FY26 revenue reached INR 814 crores with a 22% YoY EBITDA growth.
Invested INR 235 crores in new content and INR 105 crores in inorganic catalogue acquisitions in FY26.
Strategic minority stake in Bhansali Productions ensures exclusive access to marquee music for 24-30 months.
Pocket Aces reached breakeven; Artist management vertical now handles 300+ artists with 400M+ followers.
👀 What to Watch
Investors should view the strong EBITDA growth and strategic tie-up with Bhansali Productions as positive indicators of a long-term content moat. Monitor the transition to paid music subscriptions in India as a key future revenue driver for the company.
